Although endothelin receptor antagonists were not beneficial in HF, the selective ETA antagonist atrasentan has recently been shown to slow the rate of decline in kidney function in patients with diabetes and chronic kidney disease.7 Consequently, we also examined the relationship between serum ET-1 concentration and the rate of decline in eGFR over time among patients included in DAPA-HF. Here, EDN1 is linked to diabetes mellitus.